These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1374578)

  • 21. Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine.
    Lelie PN; Reesink HW; Lucas CJ
    J Med Virol; 1987 Nov; 23(3):297-301. PubMed ID: 2828525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temperature-sensitive gel for virus concentration from urine.
    Maheshkumar S; Peterson RB; Goyal SM
    J Virol Methods; 1989 Jan; 23(1):41-6. PubMed ID: 2492297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ways to reduce the risk of transmission of viral infections by plasma and plasma products. A comparison of methods, their advantages and disadvantages.
    Vox Sang; 1988; 54(4):228-45. PubMed ID: 3388821
    [No Abstract]   [Full Text] [Related]  

  • 24. Chikungunya virus and the safety of plasma products.
    Leydold SM; Farcet MR; Kindermann J; Modrof J; Pölsler G; Berting A; Howard MK; Barrett PN; Kreil TR
    Transfusion; 2012 Oct; 52(10):2122-30. PubMed ID: 22339168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Occupational risk of blood-borne viruses in healthcare workers.
    Van Laer F; Roelandt R; Coenen E
    Infect Control Hosp Epidemiol; 2002 Dec; 23(12):712. PubMed ID: 12517010
    [No Abstract]   [Full Text] [Related]  

  • 26. Resistance of porcine circovirus and chicken anemia virus to virus inactivation procedures used for blood products.
    Welch J; Bienek C; Gomperts E; Simmonds P
    Transfusion; 2006 Nov; 46(11):1951-8. PubMed ID: 17076851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement in the safety of immune globulins prepared from high-risk plasma.
    Gao F; Prince AM; Pascual D; Horowitz B
    Vox Sang; 1993; 64(4):204-9. PubMed ID: 8390765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inactivation of lipid-enveloped and non-lipid-enveloped model viruses in normal human plasma by crosslinked starch-iodine.
    Highsmith FA; Xue H; Caple M; Walthall B; Drohan WN; Shanbrom E
    Transfusion; 1994 Apr; 34(4):322-7. PubMed ID: 8178330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gamma irradiation of intravenous immunoglobulin.
    Drohan WN; Miekka SI; Griko YV; Forng RY; Stafford RE; Hill CR; Mann DM; Burgess WH
    Dev Biol (Basel); 2004; 118():133-8. PubMed ID: 15645683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new ozone-based method for virus inactivation: preliminary study.
    Kekez MM; Sattar SA
    Phys Med Biol; 1997 Nov; 42(11):2027-39. PubMed ID: 9394395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of chemical inactivation of bovine viral diarrhea virus with beta-propiolactone and binary ethyleneimine on plasma proteins and coagulation factors.
    Refaie FM; Esmat AY; Mohamed AF; Mohamed WA
    Egypt J Immunol; 2004; 11(2):9-20. PubMed ID: 16734113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation.
    Nowak T; Niedrig M; Bernhardt D; Hilfenhaus J
    Dev Biol Stand; 1993; 81():169-76. PubMed ID: 8174799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific inactivation of viruses which can potentially contaminate blood products.
    Horowitz B
    Dev Biol Stand; 1991; 75():43-52. PubMed ID: 1794631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inactivation of HIV-1 and HIV-2 by various manufacturing procedures for human plasma proteins.
    Hilfenhaus JW; Gregersen JP; Mehdi S; Volk R
    Cancer Detect Prev; 1990; 14(3):369-75. PubMed ID: 2117485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Acrylamide gel electrophoresis and gel filtration as methods of analysis for blood protein derivatives].
    Bosadjiev LG; Bineva I
    Dev Biol Stand; 1974; 27():44-8. PubMed ID: 4142775
    [No Abstract]   [Full Text] [Related]  

  • 37. Plasma temperature during methylene blue/light treatment influences virus inactivation capacity and product quality.
    Gravemann U; Handke W; Sumian C; Alvarez I; Reichenberg S; Müller TH; Seltsam A
    Vox Sang; 2018 May; 113(4):368-377. PubMed ID: 29484670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization.
    Wagner SJ; Robinette D; Storry J; Chen XY; Shumaker J; Benade L
    Transfusion; 1994 Jun; 34(6):521-6. PubMed ID: 8023394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virus inactivation/elimination in therapeutic protein concentrates.
    Mitra G; Dobkin MB; Wong MF; Mozen MM
    Curr Stud Hematol Blood Transfus; 1989; (56):34-43. PubMed ID: 2910652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
    Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
    Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.